Highest-materiality recent filing
Cerus enters $65M term loan and $30M revolver, refinancing existing debt
New term loan facility up to $65M; initial $35M drawn to refinance portion of existing term loan.
Cerus Q1 revenue up 23% to $59.9M, raises FY product revenue guidance
Product revenue $53.7M (+24% YoY); total revenue $59.9M (+23% YoY).
Cerus reports FY2025 revenue $233.8M (+16%); net loss narrows to $15.6M
FY2025 product revenue $206.1M (+14%); total revenue $233.8M (+16%).
Cerus reports preliminary FY 2025 product revenue of $206.1M (+14% YoY); guides FY 2026 to $224-228M
Q4 2025 preliminary product revenue $57.8M, up 14% YoY; IFC revenue $4.2M (+40% YoY).
Cerus Q3 revenue up 19% to $60.2M, raises FY2025 product revenue guidance
Product revenue $52.7M (+15% YoY); total revenue $60.2M (+19% YoY).
Cerus Q2 product revenue $52.4M (+16% YoY); raises FY2025 guidance to $200-203M
Q2 product revenue record $52.4M, up 16% YoY; total revenue $60.1M, up 19% YoY.
Cerus Q1 product revenue up 13% to $43.2M; net loss narrows to $7.7M; reaffirms FY guidance
Product revenue $43.2M (+13% YoY); total revenue $48.9M incl. $5.6M gov't contract.
Cerus FY2024 product revenue up 15% to $180.3M; GAAP net loss narrows to $20.9M
Total revenue FY2024 $201.3M (+8% YoY); product revenue $180.3M (+15% YoY).
Cerus prelim FY2024 product revenue $180.3M (+15% YoY), above guidance; FY2025 guidance $194-200M
FY2024 product revenue $180.3M, up 15% YoY, exceeding prior guidance of $177-179M.
Cerus Q3 product revenue $46.0M (+16% YoY); raises FY2024 guidance to $177-179M
Net loss narrowed to $2.9M ($0.02/sh) from $7.3M; positive non-GAAP adjusted EBITDA of $4.4M.
Cerus gets $248M BARDA contract for RBC program; EU CE Mark review denied
New BARDA contract valued up to $248M to support U.S. INTERCEPT RBC system development and PMA submission; $32.1M awarded for base period.
Cerus Q2 product revenue up 16% to $45M; raises FY2024 guidance to $175-178M
Q2 product revenue $45.1M (+16% YoY); total revenue $50.5M (+6% YoY).
Cerus Q1 product revenue up 24% to $38.4M; net loss narrows to $9.7M; ReCePI trial met endpoint
Q1 product revenue $38.4M (+24% YoY); total revenue $43.4M (+13%).
Cerus INTERCEPT RBC Phase 3 trial meets primary non-inferiority endpoint
AKI incidence 29.3% (INTERCEPT RBC) vs 28.0% (conventional); non-inferiority margin 14% (p=0.001).
Cerus Q4 net loss narrows to $1.3M; achieves adj. EBITDA breakeven; reiterates FY2024 guidance
Q4 net loss attributable to Cerus narrowed to $1.3M ($0.01/share) from $13.6M ($0.08) a year ago.
Cerus reports preliminary Q4 product revenue $46.8M; FY 2024 guidance $172-175M
Preliminary Q4 2023 product revenue $46.8M, +6% YoY and +18% sequential; FY 2023 revenue $156.4M in line with guidance.
CERS Q3 product revenue $39.8M, net loss $7.3M; FY product revenue guidance cut to $155-158M
Total Q3 revenue $47.3M ($39.8M product, $7.5M govt); net loss $7.3M ($0.04/share) vs $8.5M loss year ago.
Cerus Q2 net loss $13.3M, cuts FY product revenue guidance to $160-165M
Q2 total revenue $47.7M (product $38.9M, govt $8.9M); net loss $13.3M ($0.07/sh) vs $8.4M loss a year ago.
Cerus Q1 revenue down 11% to $38.5M; net loss widens to $15.6M; reiterates FY guidance
Product revenue $31.0M (-17% YoY) on US inventory drawdown; govt contract revenue $7.5M (+35%).
Cerus enters into $75M term loan and $20M revolver credit agreements with MidCap
Borrowed $40M (Tranche 1) and $15M (Tranche 2) on closing to refinance existing term loans.
Cerus reports record Q4 product revenue of $44.0M, up 10% YoY; reiterates FY2023 guidance $165-170M
Q4 product revenue $44.0M (+10% YoY); full-year product revenue $162.0M (+24% YoY).
Preliminary Q4 2022 product revenue $44.0M, up 10% from Q4 2021.
Cerus Q3 revenue up 10% to $46.3M; narrows FY product revenue guidance to $160-162M
Net loss improved to $8.5M ($0.05/sh) from $12.4M ($0.07/sh) in Q3 2021.
Cerus Q2 product revenue $41M (up 30% YoY), net loss narrows to $8.4M; reaffirms FY22 guide
Total revenue $47.6M (+26% YoY); product revenue $41.0M (+30% YoY), a company record.
Cerus Q1 total revenue $43.0M (+46% YoY); raises FY product revenue guidance to $160-165M
Product revenue $37.4M (+60% YoY) driven by INTERCEPT platelet kit sales in the U.S.
Cerus Q4 revenue $50.1M (+49% YoY); reiterates FY2022 product revenue guidance $157-164M
Q4 product revenue $39.9M (+41% YoY); net loss narrowed to $9.1M ($0.05/sh) from $14.4M.
Cerus reports record preliminary Q4/FY2021 product revenue, guides 2022 up 20-25%
Q4 2021 preliminary product revenue $39.9M, up 41% YoY from $28.2M.
Cerus Q3 product revenue $36.1M (+53% YoY); raises FY21 guidance to $127-129M
Total revenue $42.1M (+44% YoY); product revenue $36.1M (+53% YoY) driven by U.S. INTERCEPT platelet adoption.
Cerus Q2 revenue $37.8M (+41% YoY); raises FY product revenue guidance to $118-122M
Total revenue $37.8M (+41% YoY); product revenue $31.5M (+46%) led by 128% North America platelet growth.
William “Obi” Greenman, former President and Chief Executive Officer and Chairman of the Board of Directors (the “Board”) of Cerus Corporation (the “Company”), ceased serving as President and Chief Executive Officer and began serving as Executive Chairman of the Board effective July 1, 2026 (the “Effective Date”).
on June 20, 2025, the Board appointed William M. Greenman, the Company’s President and Chief Executive Officer and a member of the class of directors whose terms of office expire at the Company’s 2026 annual meeting of stockholders, to serve as chair of the Board
On June 16, 2025, Daniel N. Swisher, Jr., chair of the board of directors (the “Board”) of Cerus Corporation (the “Company”), notified the Company of his intent to retire from the Board and all committees thereof on which he served, effective immediately.
On February 2, 2025, Gail Schulze, a member of the class of directors whose terms of office expire at the 2025 annual meeting of stockholders (the “2025 Annual Meeting”) of Cerus Corporation (the “Company”), informed the Company that she would not stand for re-election at the 2025 Annual Meeting.
the Board extended an offer to join the Board to Dean Gregory, and on July 1, 2024, Mr. Gregory accepted such offer to join the Board, effective July 1, 2024.
the Board extended an offer to join the Board to Hua Shan, MD, PhD, and on June 30, 2022, Dr. Shan accepted such offer to join the Board, effective July 1, 2022.
Max materiality 0.85 · Median 0.70 · Most common event earnings